OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.

Xu, Feng; Yu, Yinhua; Daly, L.; DeSombre, K.; Anselmino, Lisa; Hass, George M.; Berchuck, Andrew; Soper, John T.; Clarke‐Pearson, Daniel L.; Boyer, Cinda M.

doi:10.1200/jco.1993.11.8.1506

Cited by 44 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10 The OVX1 assay measures a modified Lewis X determinant on mucin recognized by a murine monoclonal antibody. 11 OVX1 levels were elevated (Ͼ 12.1 U/mL) in sera from 67% of patients who had clinically evident ovarian carcinoma despite normal serum CA-125 levels Ͻ 35 U/mL.…”

mentioning

confidence: 99%

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma

Haaften-Day

Shen

et al. 2001

Cancer

View full text Add to dashboard Cite

mentioning

confidence: 99%

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma

Haaften-Day

Shen

et al. 2001

Cancer

View full text Add to dashboard Cite

“…M-CSF complements CA125 in the identification of ovarian cancer patients, increasing sensitivity from 64% to 90% using the criteria that one or both markers were elevated [101]. A Lewis X mucin determinant (OVX1) also complements M-CSF in distinguishing stage I ovarian cancers from healthy controls [101,102], with an improvement in sensitivity, but with a considerable loss in specificity as described above. A confirmatory study evaluated the combination of CA125II, M-CSF and OVX1 [27].…”

Section: Macrophage Colony Stimulating Factormentioning

confidence: 99%

“…When the two markers were considered together, the sensitivity improved to 91% but the sensitivity decreased to 65% [69]. Our group has evaluated a Lewis X mucin determinant (OVX1) and the cytokine macrophage colony-stimulating factor (M-CSF) for their ability to detect stage I ovarian cancer and to complement CA125 [101,102]. Among 89 serum samples obtained from patients with stage I ovarian cancer before surgery, CA125 was greater than 35 U/mL in 69%.…”

Section: Multiple Markers May Improve Sensitivity and Specificitymentioning

confidence: 99%

Early Detection of Ovarian Cancer

Das

Bast

2008

Biomarkers Med.

View full text Add to dashboard Cite

Abstract. Despite advances in therapy, ovarian cancer remains the most deadly of the gynecological cancers. Less than 30% of women with advanced stage disease survive long-term. When diagnosed in stage I, up to 90% of patients can be cured with conventional surgery and chemotherapy. At present, only 25% of ovarian cancers are detected in stage I due, in part, to the absence of specific symptoms and to lack of an effective screening strategy. Early detection of ovarian cancer might significantly improve the overall survival rate of women with ovarian cancer if 1) most cancers are clonal and unifocal, arising in the ovary rather than in the peritoneum, 2) metastatic disease results from progression of clinically detectable stage I lesions, and 3) cancers remain localized for a sufficient interval to permit cost-effective screening. Given the prevalence of ovarian cancer, strategies for early detection must have high sensitivity for early stage disease (>75%), but must have extremely high specificity (99.6%) to attain a positive predictive value of at least 10%. Transvaginal sonography (TVS), serum markers and a combination of the two modalities have been evaluated for early detection of ovarian cancer. Among the serum markers, CA125 has received the most attention, but lacks the sensitivity or specificity to function alone as a screening test. Greater specificity can be achieved by combining CA125 and TVS and/or by monitoring CA125 over time. Two stage screening strategies promise to be cost effective, where abnormal serum assays prompt TVS to detect lesions that require laparotomy. Accrual has been completed for a 200,000 woman trial in the United Kingdom that will test the ability of a rising CA125 to trigger TVS and subsequent exploratory surgery. Given the heterogeneity of ovarian cancer, it is unlikely that any single marker will be sufficiently sensitive to provide an effective initial screen. Sensitivity of serum assays might be enhanced by utilizing a panel of biomarkers. Candidate biomarkers have been discovered through empirical development of monoclonal antibodies, studies of gene expression, cloning of gene families and proteomic techniques. The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise.

show abstract

“…OVX was found to be elevated in 67% of patients with ovarian cancer who were CA-125 negative (48,49).…”

Section: Serum Markers For Ovarian Cancermentioning

confidence: 99%

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Kobayashi

Ueda

Matsuzaki

et al. 2012

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Serum tumor markers have a major role in the screening, diagnosis, and monitoring of most of the gynecologic cancers. Ovarian cancer is one of the deadliest of the group because it is so frequently asymptomatic until it has advanced to an untreatable stage. Even serum cancer antigen-125 (CA-125), clinically one of the most reliable serum markers for ovarian cancer, is elevated in only half of early-stage still-treatable tumors. Because of the very low prevalence of ovarian cancer in the general population, at present, there is no cost-effective imaging or simple microscopic screening test for ovarian cancer as there is for breast and cervical cancers. However, recent proteomics and nucleic acid-based analyses have shown great promise for the discovery of new and more useful serum biomarkers, which cumulatively might provide such a screening tool. In this review, we will discuss both the currently used serum tumor markers for screening, diagnosis, monitoring of ovarian cancer, and the novel biomarkers that are now under investigation and validation.

show abstract

OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.

Abstract: An elevated OVX1 level can alert oncologists to the possibility that ovarian cancer has persisted, despite the return of CA-125 to a normal range.

Cited by 44 publications

References 10 publications

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma

OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma

Early Detection of Ovarian Cancer

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Contact Info

Product

Resources

About